A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care

This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany.

Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Moderate to Severe Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Gemeinschaftspraxis Innere Medizin/Rheumatologie /ID# 278584, Freiburg im Breisgau, Baden-Wurttemberg, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician.
Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study
UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies

Exclusion criteria

Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug [whichever is longer] prior to baseline)
Prior treatment with Upadacitinib
Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study

Treatment and study plan

Primary outcomes

Retention Rate of UPA vs TNFi

Time frame: Up to approximately 24 months

Time to the discontinuation of Upadacitinib. Time to the discontinuation of Tumor Necrosis Factor Inhibitor treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Medical Information Germany

CONTACT

[email protected]

49 611 1720 1520

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Acronym: UP-RISING

Important dates

Study start: 2024
Primary completion: 2028
Study completion: 2028
First posted: Dec 2, 2024
Registry last updated: Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting